George F. Vande Woude mainly investigates Cancer research, Hepatocyte growth factor, Molecular biology, Tyrosine kinase and Receptor tyrosine kinase. His biological study spans a wide range of topics, including Carcinogenesis, Cancer, Metastasis, Signal transduction and C-Met. His Cancer study incorporates themes from c-Met inhibitor and Endocrinology.
George F. Vande Woude focuses mostly in the field of Signal transduction, narrowing it down to matters related to Receptor and, in some cases, In vivo. His work carried out in the field of Hepatocyte growth factor brings together such families of science as Cell, Thrombospondin 1, STAT protein and Cell biology. His Molecular biology study combines topics in areas such as Meiosis, RNA, Xenopus, Proto-Oncogene Proteins c-met and Kinase.
George F. Vande Woude spends much of his time researching Cancer research, Hepatocyte growth factor, Molecular biology, Cancer and Receptor tyrosine kinase. His studies deal with areas such as Paracrine signalling, Tyrosine kinase, Signal transduction, Immunology and Metastasis as well as Cancer research. The various areas that George F. Vande Woude examines in his Hepatocyte growth factor study include Autocrine signalling, Cell growth and Cell biology.
George F. Vande Woude interconnects Cell culture, Genetics, RNA, Xenopus and Proto-Oncogene Proteins c-met in the investigation of issues within Molecular biology. His Cancer study combines topics from a wide range of disciplines, such as Lung cancer and Oncology. His work deals with themes such as Carcinogenesis and Monoclonal antibody, which intersect with Receptor tyrosine kinase.
The scientist’s investigation covers issues in Cancer research, Hepatocyte growth factor, Receptor tyrosine kinase, Cancer and Signal transduction. His Cancer research research is multidisciplinary, incorporating perspectives in Tyrosine kinase, Proto-oncogene tyrosine-protein kinase Src, Breast cancer, PI3K/AKT/mTOR pathway and Monoclonal antibody. The concepts of his Hepatocyte growth factor study are interwoven with issues in Targeted therapy and Mechanism of action.
His studies in Receptor tyrosine kinase integrate themes in fields like Onartuzumab, Coiled coil, Binding site and MAPK/ERK pathway. He is studying Cancer cell, which is a component of Cancer. His study on Signal transduction also encompasses disciplines like
George F. Vande Woude mainly focuses on Cancer research, Receptor tyrosine kinase, Hepatocyte growth factor, Signal transduction and Tyrosine kinase. George F. Vande Woude has researched Cancer research in several fields, including Molecular biology, Targeted therapy and Hepatitis B virus. His work on ERBB3 as part of general Receptor tyrosine kinase study is frequently linked to Context, bridging the gap between disciplines.
George F. Vande Woude combines subjects such as Hepatitis B, Cancer, Bioinformatics and Hepatitis with his study of Hepatocyte growth factor. George F. Vande Woude has included themes like Cell growth, Erlotinib Hydrochloride, Erlotinib, EGFR inhibitors and Pharmacology in his Signal transduction study. The study incorporates disciplines such as Protein kinase B, Gene knockdown, Breast cancer, PI3K/AKT/mTOR pathway and MAPK/ERK pathway in addition to Tyrosine kinase.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Met, metastasis, motility and more
Carmen Birchmeier;Walter Birchmeier;Ermanno Gherardi;George F. Vande Woude.
Nature Reviews Molecular Cell Biology (2003)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi;Ermanno Gherardi;Walter Birchmeier;Carmen Birchmeier;George Vande Woude.
Nature Reviews Cancer (2012)
Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor
Nicholas S. Duesbery;Craig P. Webb;Stephen H. Leppla;Valery M. Gordon.
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Colin S. Cooper;Morag Park;Donald G. Blair;Michael A. Tainsky.
Abnormal Centrosome Amplification in the Absence of p53
Kenji Fukasawa;Taesaeng Choi;Ryoko Kuriyama;Shen Rulong.
Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes
Noriyuki Sagata;Marianne Oskarsson;Terry Copeland;John Brumbaugh.
Mechanism of met oncogene activation
Morag Park;Michael Dean;Colin S. Cooper;Martin Schmidt.
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder;George F. Vande Woude;Scott A. Boerner;Patricia M. LoRusso.
Clinical Cancer Research (2009)
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
Kyle A Furge;Yu-Wen Zhang;George F Vande Woude.
Activating mutations for the Met tyrosine kinase receptor in human cancer
Michael Jeffers;Laura Schmidt;Noboru Nakaigawa;Craig P. Webb.
Proceedings of the National Academy of Sciences of the United States of America (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: